Clinical Trial Applications - Approved: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | Date Approved | |
|---|---|---|---|---|---|
401. |
ECCT/21/07/03 | GBT_131 Inclacumab-Ps 3 Trial. A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Inclacumab in Participants with Sickle Cell Disease Experiencing Vaso-occlusive Crises |
Principal Investigator(s) 1. Prof Jessie N Githanga 2. Fredrick Sirwa Chite 3. Bernhards Ragama Ogutu 4. Videlis N Nduba Site(s) in Kenya 1. International Cancer Institute (ICI)-Eldorate (Uasin Gishu county) 2. KEMRI/CRDR (Nairobi City county) 3. KEMRI Siaya Clinical Research Annex (Siaya county) 4. Gertrude’s Children’s Hospital. (Nairobi City county) 5. Strathmore University Medical Centre (Nairobi City county) |
08-11-2021 |
View |
402. |
ECCT/21/11/08 | GBT_131 Inclacumab-Ps 3 Trial. A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Inclacumab in Participants with Sickle Cell Disease Experiencing Vaso-occlusive Crises |
Principal Investigator(s) 1. Videlis N Nduba 2. Prof. Jessie N Githanga 3. Fredrick Sirwa Chite 4. Bernhards Ragama Ogutu Site(s) in Kenya 1. KEMRI/CRDR (Nairobi City county) 2. KEMRI Siaya Clinical Research Annex (Siaya county) 3. Gertrude’s Children’s Hospital. (Nairobi City county) 4. Strathmore University Medical Centre (Nairobi City county) 5. International Cancer Institute (ICI)-Eldorate (Uasin Gishu county) |
02-02-2022 |
View |
403. |
ECCT/21/11/04 | GBT_131 Inclacumab-Ps 3 Trial. A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Inclacumab in Participants with Sickle Cell Disease Experiencing Vaso-occlusive Crises |
Principal Investigator(s) 1. Fredrick Sirwa Chite 2. Prof Jessie N Githanga 3. Bernhards Ragama Ogutu 4. Videlis N Nduba Site(s) in Kenya 1. International Cancer Institute (ICI)-Eldorate (Uasin Gishu county) 2. KEMRI/CRDR (Nairobi City county) 3. KEMRI Siaya Clinical Research Annex (Siaya county) 4. Gertrude’s Children’s Hospital. (Nairobi City county) 5. Strathmore University Medical Centre (Nairobi City county) |
21-12-2021 |
View |
404. |
ECCT/21/12/05 | 131 Inclacumab Ph 3 Trial. A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Inclacumab in Participants with Sickle Cell Disease Experiencing Vasoocclusive Crises |
Principal Investigator(s) 1. Bernhards Ragama Ogutu 2. Fredrick Asirwa Chite 3. Videlis N Nduba 4. Prof. Jessie N Githanga Site(s) in Kenya 1. Strathmore University Medical Centre (Nairobi City county) 2. KEMRI/CRDR (Nairobi City county) 3. KEMRI Siaya Clinical Research Annex (Siaya county) 4. Gertrude’s Children’s Hospital. (Nairobi City county) 5. International Cancer Institute (ICI)-Eldorate (Uasin Gishu county) |
22-03-2022 |
View |
405. |
ECCT/19/05/01 | A randomized, double-blinded, placebo-controlled, dose-escalation phase 1 clinical trial to evaluate the safety and immunogenicity of recombinant HIV envelope protein BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, in healthy, HIV--1 uninfected adults A randomized, double-blinded, placebo-controlled, dose-escalation phase 1 clinical trial to evaluate the safety and immunogenicity of recombinant HIV envelope protein BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, in healthy, HIV--1 uninfected adults |
Principal Investigator(s) 1. Omu Anzala Site(s) in Kenya KAVI-ICR KNH SITE |
08-07-2019 |
View |
406. |
ECCT/15/05/01 | Janssen Ebola vaccine study A Randomized, Observer-blind, Placebo-controlled, Phase 2 Study to Evaluate the Safety, Tolerability and Immunogenicity of Different Prime-boost Regimens of the Candidate Prophylactic Vaccines for Ebola Ad26.ZEBOV and MVA-BN-Filo in Healthy Adults, Including Elderly Subjects, HIV-infected Subjects, and Healthy Children in Two Age Strata in Africa |
Principal Investigator(s) 1. Prof Omu Aggrey Anzala Site(s) in Kenya KAVI –Institute of Clinical Research |
17-12-2015 |
View |
407. |
ECCT/16/11/04 | RV456 A Randomized, Observer-blind, Placebo-controlled, Two part, Phase 2 Study to Evaluate the Safety, Tolerability and Immunogenicity of Two Prime-boost Regimens of the Candidate Prophylactic Vaccines for Ebola Ad26.ZEBOV and MVA-BN-Filo |
Principal Investigator(s) 1. JANET OYIEKO Site(s) in Kenya KOMBEWA CLINICAL RESEARCH CENTRE |
28-01-2017 |
View |
408. |
ECCT/16/11/05 | RV 456: Vaccines for Ebola Ad26.ZEBOV and MVA-BN-Filo A randomized, obsever-blind, placebo controlled, two-part, Phase 2 study to evaluate the Safety, Tolerability and Immunogenicity of Two prime-boost regimen of the candidate Prophylactic vaccines for Ebola Ad26-ZEBOV and MVA-BN Filo. |
Principal Investigator(s) 1. Fredrick Kipyego Sawe Site(s) in Kenya 1. KEMRI/WRP Kericho (Kericho county) 2. KEMRI/WRP Kombewa, Kisumu (Kisumu county) |
02-03-2017 |
View |
409. |
ECCT/18/07/07 | A Randomized, Open, Parallel-group, Single Dose, Phase 2a Study, to Investigate the Clinical and Parasiticidal Activity and the Pharmacokinetics of 3 dose levels of Artefenomel in combination with Ferroquine (FQ) and FQ alone, in African Patients with Unc A Randomized, Open label, Parallel-group, Single Dose Regimen, Phase 2a Study, to Investigate the Clinical and Parasiticidal Activity and the Pharmacokinetics of 3 dose levels of Artefenomel (OZ439) given in combination with Ferroquine (FQ) and FQ alone, in African Patients with Uncomplicated Plasmodium falciparum Malaria |
Principal Investigator(s) 1. GRACE KIRINGA KAGUTHI Site(s) in Kenya 1. Center for Respiratory Diseases Research (Siaya county) 2. KEMRI (Kisumu county) |
04-10-2018 |
View |
410. |
ECCT/19/01/01 | A Randomized, Open, Parallel-group, Single Dose, Phase 2a Study, to Investigate the Clinical and Parasiticidal Activity and the Pharmacokinetics of 3 dose levels of Artefenomel in combination with Ferroquine (FQ) and FQ alone, in African Patients with Unc A Randomized, Open label, Parallel-group, Single Dose Regimen, Phase 2a Study, to Investigate the Clinical and Parasiticidal Activity and the Pharmacokinetics of 3 dose levels of Artefenomel (OZ439) given in combination with Ferroquine (FQ) and FQ alone, in African Patients with Uncomplicated Plasmodium falciparum Malaria |
Principal Investigator(s) 1. Bernhards Ogutu Ragama Site(s) in Kenya 1. Ahero County hospital (Kisumu county) 2. Siaya County Hospital (Siaya county) |
13-08-2019 |
View |